JMP Securities Raises CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $80.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price raised by JMP Securities from $74.00 to $80.00 in a report released on Monday, Benzinga reports. They currently have a market outperform rating on the stock. A number of other research firms also recently weighed in on CRSP. Truist Financial restated a buy rating on […]
More Stories
Amazon.com, Inc. (NASDAQ:AMZN) Stock Position Increased by Quadcap Wealth Management LLC
Quadcap Wealth Management LLC grew its stake in shares of Amazon.com, Inc. (NASDAQ:AMZN) by 3.2% during the fourth quarter, according...
Main Management ETF Advisors LLC Sells 3,904 Shares of NVIDIA Co. (NASDAQ:NVDA)
Main Management ETF Advisors LLC reduced its holdings in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 8.2% during...
Nuveen Asset Management LLC Increases Holdings in Sonic Automotive, Inc. (NYSE:SAH)
Nuveen Asset Management LLC grew its holdings in Sonic Automotive, Inc. (NYSE:SAH – Free Report) by 1.1% during the 4th...
Squarepoint Ops LLC Has $2.23 Million Stake in Alignment Healthcare, Inc. (NASDAQ:ALHC)
Squarepoint Ops LLC increased its holdings in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC – Free Report) by 414.6% in the...
MainStreet Investment Advisors LLC Lowers Stock Position in Amazon.com, Inc. (NASDAQ:AMZN)
MainStreet Investment Advisors LLC cut its stake in shares of Amazon.com, Inc. (NASDAQ:AMZN) by 2.1% in the 4th quarter, Holdings...
Deutsche Bank AG Buys 31,841 Shares of FTAI Infrastructure Inc. (NASDAQ:FIP)
Deutsche Bank AG grew its holdings in FTAI Infrastructure Inc. (NASDAQ:FIP – Free Report) by 52.7% in the fourth quarter,...